CoChat
Sign Up
Cited by 230

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis: A Randomized Placebo-controlled Trial

Nelson, Austin, Torres, Dawn M., Morgan, Ana E., Fincke, Christopher, Harrison, Stephen A.·2009·Journal of Clinical Gastroenterology
DOI 10.1097/mcg.0b013e31819c392e
Open this paper in CoChat — free account

Abstract

Goals This study was designed to assess the utility of statin therapy in patients with biopsy proven nonalcoholic steatohepatitis (NASH) and hyperlipidemia. Background Nonalcoholic fatty liver disease, as the hepatic manifestation of the metabolic syndrome, has become a growing public health concern. Nonalcoholic steatohepatitis (NASH) represents a subset of nonalcoholic fatty liver disease manifested by hepatic fatty infiltration and inflammation which may progress to cirrhosis and its subsequent complications, to include hepatocellular carcinoma. As the metabolic syndrome is thought to be central in the pathogenesis of NASH, it has been speculated that medications that improve metabolic profiles may be beneficial in treatment. In fact, recent studies have demonstrated potential benefit of 3-hydroxy-3-methyglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), which are used in clinical practice to improve lipid panels. Study This double-blinded randomized placebo-controlled trial compared the HMG-CoA reductase inhibitor, simvastatin, with placebo in the treatment of NASH over a 12-month period using serum aminotransferases and repeat liver biopsy to assess for improvement. Results Sixteen patients with biopsy proven NASH were enrolled: 14 completed the study and 10 underwent 1-year repeat liver biopsy. Mean age: 53 years (+/-10.1), mean body mass index: 32.4 (+/-6.1) with 11 male and 5 female patients. Although a 26% reduction in low-density lipoprotein was seen in t…

Overview

Integrity signals

Registry

Crossref · 10.1097/mcg.0b013e31819c392e

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Other randomized trials with statins showed no significant improvement in liver histological features of MASH patients.

    “although other randomized trials with statins showed no significant improvement in liver histological features of MASH patients94”

    From EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis (2025) · cites this paper as [94]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. Machado, 2006, Hepatic histology in obese patients undergoing bariatric surgery, J Hepatol, 45, 600, 10.1016/j.jhep.2006.06.013 · DOI
  2. Wanless, 1990, Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors, Hepatology, 12, 1106, 10.1002/hep.1840120505 · DOI · Paper page
  3. Harrison, 2004, Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Clin Liver Dis, 8, 861, 10.1016/j.cld.2004.06.008 · DOI
  4. Defronso, 1991, Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease, Diabetes Care, 14, 173, 10.2337/diacare.14.3.173 · DOI
  5. Day, 1998, Steatohepatitis: a tale of two “hits”? [editorial], Gastroenterology, 114, 842, 10.1016/S0016-5085(98)70599-2 · DOI · Paper page
  6. Kaplan, 1998, Leptin, obesity, and liver disease, Gastroenterology, 115, 997, 10.1016/S0016-5085(98)70272-0 · DOI
  7. Harrison, 2002, Nonalcoholic Steatohepatitis: what we know in the new millennium, Am J Gastroenterol, 97, 2714
  8. Adams, 2005, The natural history of nonalcoholic fatty liver, Gastroenteroloy, 129, 113, 10.1053/j.gastro.2005.04.014 · DOI · Paper page
  9. Hussein, 2007, Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH), Dig Dis Sci, 52, 2512, 10.1007/s10620-006-9631-1 · DOI
  10. Harrison, 2003, Vitamin E and C treatment improves fibrosis in patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 98, 2485, 10.1111/j.1572-0241.2003.08699.x · DOI
  11. Sanyal, 2004, A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 2, 1107, 10.1016/S1542-3565(04)00457-4 · DOI
  12. Merat, 2003, Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study, J Clin Gastroenterol, 36, 266, 10.1097/00004836-200303000-00015 · DOI
  13. Deushi, 2007, Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome, FEBS Lett, 581, 5664, 10.1016/j.febslet.2007.11.023 · DOI
  14. Yokohama, 2004, Therapeutic efficacy of an antiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis, Hepatology, 40, 1222, 10.1002/hep.20420 · DOI
  15. Bugianesi, 2005, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease, Am J Gastroenterol, 100, 1082, 10.1111/j.1572-0241.2005.41583.x · DOI
  16. Georgescu, 2007, Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a Preliminary Study, J Gastrointestinal Liver Dis, 16, 39
  17. Gomez-Dominguez, 2006, A pilot study of atorvastatin treatment in dyslipdemidic, non-alcoholic fatty liver patients, Aliment Pharmacol Ther, 23, 1643, 10.1111/j.1365-2036.2006.02926.x · DOI
  18. Rallidis, 2004, Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Letter to the Editor, Artherosclerosis, 174, 193, 10.1016/j.atherosclerosis.2004.01.008 · DOI
  19. Brunt, 1999, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, Am J Gastroenterol, 94, 2467, 10.1111/j.1572-0241.1999.01377.x · DOI · Paper page
  20. Sridevi, 2007, Simvastatin (40 mg/d), adiponectin levels, and insulin sensitivity in subjects with metabolic syndrome, Am J Cardiol, 100, 1397, 10.1016/j.amjcard.2007.06.028 · DOI
  21. Bravo, 2001, Liver biopsy, N Engl J Med, 344, 495, 10.1056/NEJM200102153440706 · DOI
  22. Leclercq, 2000, CYP2E1 and CYP4A as microsomal catalyst of lipid peroxides in murine nonalcoholic steatohepatitis, J Clin Invest, 105, 1067, 10.1172/JCI8814 · DOI
  23. Klover, 2003, Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice, Diabetes, 52, 2784, 10.2337/diabetes.52.11.2784 · DOI · Paper page
  24. Tsochatzis, 2006, The evolving role of leptin and adiponectin in chronic liver diseases, Am J Gastroenterol, 101, 2629, 10.1111/j.1572-0241.2006.00848.x · DOI
  25. Anania, 2007, Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease, Gastroenterol, 132, 2191, 10.1053/j.gastro.2007.03.055 · DOI
  26. Chitturi, 2002, Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?, Hepatology, 36, 403, 10.1053/jhep.2002.34738 · DOI
  27. Nakao, 2002, Association between nonalcoholic fatty liver, markers of obesity, and serum leptin levels in young adults, Am J Gastroenterol, 97, 1796, 10.1111/j.1572-0241.2002.05846.x · DOI
  28. Targher, 2006, Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease, Clin Endocrinology, 64, 679, 10.1111/j.1365-2265.2006.02527.x · DOI
  29. Devaraj, 2006, Direct demonstration of an anti-inflammatory effect of simvastatin in subjects with the metabolic syndrome, J Clin Endocrinol Metab, 91, 4489, 10.1210/jc.2006-0299 · DOI
  30. Zhao, 2005, Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits, Clin Chim Acta, 360, 133, 10.1016/j.cccn.2005.04.021 · DOI
  31. Blanco-Colio, 2008, Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk, Eur J Pharmacol, 586, 259, 10.1016/j.ejphar.2008.02.042 · DOI
  32. Chu, 2008, Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes, J Endocrinol Invest, 31, 42, 10.1007/BF03345565 · DOI
  33. Chan, 2004, A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients, Diabetes Res Clin Prac, 66, 97, 10.1016/j.diabres.2004.06.007 · DOI

Cited by

Sorted by citations

Metadata

Authors
Nelson, A., Torres, D. M., Morgan, A. E., Fincke, C., & Harrison, S. A.
Venue
Journal of Clinical Gastroenterology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2009-11
Volume
43
Issue
10
Pages
990-994
ISSN
0192-0790
DOI
10.1097/mcg.0b013e31819c392e
Cited by
230
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review